Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension

Kereiakes, Dean J.; Maa, Jen-Fue; Shojaee, Ali; Dubiel, Robert

doi:10.2165/11538630-000000000-00000

Cited by 4 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, also mean daytime and mean 24-hr SBP and DBP were significantly lowered with the ARB/thiazide combination treatment compared to monotherapy. [21][22][23][24] These results have also been confirmed in the elderly patients aged 65 years or older.…”

supporting

confidence: 57%

Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations

Gallo¹,

Volpe²,

Rubattu³

2022

VHRM

View full text Add to dashboard Cite

Hypertension represents a major common cardiovascular risk factor. Optimal control of high blood pressure levels is recommended to reduce the global burden of hypertensive-mediated organ damage and cardiovascular (CV) events. Among the firstline drugs recommended in international guidelines, renin-angiotensin-aldosterone system antagonists [angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs)] have long represented a rational, effective, and safe anti-hypertensive pharmacological strategy. In fact, current US and European guidelines recommend ACEi and ARBs as a suitable first choice for hypertension treatment together with calcium channel blockers (CCBs) and thiazide diuretics. Different studies have demonstrated that ARBs and ACEi exert a comparable effect in lowering blood pressure levels. However, ARBs are characterized by better pharmacological tolerability. Most importantly, the clinical evidence supports a relevant protective role of ARBs toward the CV and renal damage development, as well as the occurrence of major adverse CV events, in hypertensive patients. Moreover, a neutral metabolic effect has been reported upon ARBs administration, in contrast to other antihypertensive agents, such as beta-blockers and diuretics. These properties highlight the use of ARBs as an excellent pharmacological strategy to manage hypertension and its dangerous consequences. The present review article summarizes the available evidence regarding the beneficial effects and current recommendations of ARBs in hypertension. The specific properties performed by these agents in various clinical subsets are discussed, also including an overview of their implications for the current COVID-19 pandemic.

show abstract

supporting

confidence: 57%

Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations

Gallo¹,

Volpe²,

Rubattu³

2022

VHRM

View full text Add to dashboard Cite

show abstract

“…After week 8 of treatment, all OLM/ HCTZ combination therapies produced greater reductions in both systolic and diastolic BP than did monotherapy with single component [42]. The Effect of an OLM-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension (BENIFORCE) was a randomized, double-blind, placebo-controlled, titration dose trial in 276 patients with arterial hypertension stage 1 or 2 [43]. After a run-in period with placebo, patients were randomized to placebo or OLM for 12 weeks.…”

Section: Olmesartan/hydrochlorothiazide Combination Therapymentioning

confidence: 99%

“…After a run-in period with placebo, patients were randomized to placebo or OLM for 12 weeks. If BP was ≥ 120/80 mmHg, patients were up-titrated in a stepwise fashion from monotherapy with OLM 20 mg (weeks 1-3), to OLM 40 mg (weeks 4-6), OLM/HCTZ 40/12.5 mg (weeks 7-9) and then to OLM/HCTZ 40/25 (weeks 10-12) [43]. At week 12, the OLM-based treatment regimen provided a significantly greater reduction of mean sitting BP values compared with placebo [43].…”

Section: Olmesartan/hydrochlorothiazide Combination Therapymentioning

confidence: 99%

ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients

Presta

Figliuzzi

Citoni

et al. 2021

High Blood Press Cardiovasc Prev

View full text Add to dashboard Cite

Essential hypertension is the most common cardiovascular (CV) risk factor, being primarily involved in the pathogenesis of CV disease and mortality worldwide. Given the high prevalence and growing incidence of this clinical condition in the general population in both high and low-income countries, antihypertensive drug therapies are frequently prescribed in different hypertension-related CV diseases and comorbidities. Among these conditions, evidence are available demonstrating the clinical benefits of lowering blood pressure (BP) levels, particularly in those hypertensive patients at high or very high CV risk profile. Preliminary studies, performed during the Sars-COVID-19 epidemic, raised some concerns on the potential implication of hypertension and antihypertensive medications in the susceptibility of having severe pneumonia, particularly with regard to the use of drugs inhibiting the renin-angiotensin system (RAS), including angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These hypotheses were not confirmed by subsequent studies, which independently and systematically demonstrated no clinical harm of these drugs also in patients with Sars-COVID-19 infection. The aim of this narrative review is to critically discuss the available evidence supporting the use of antihypertensive therapies based RAS blocking agents in hypertensive patients with different CV risk profile and with additional clinical conditions or comorbidities, including Sars-COVID-19 infection, with a particular focus on single-pill combination therapies based on olmesartan medoxomil.

show abstract

Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide

Lyseng‐Williamson

2016

Drugs Ther Perspect

View full text Add to dashboard Cite

Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension

Abstract: An olmesartan medoxomil-based treatment algorithm effectively reduced SBP and achieved SBP targets in patients with stage 1 or 2 hypertension. This regimen resulted in >80% of patients achieving SBP reductions of ≥15 mmHg while 44% achieved SBP reductions of >30 mmHg.

Cited by 4 publications

References 23 publications

Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations

Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations

ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients

Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide

Contact Info

Product

Resources

About